Data Insights
By Company Name
No filters selected
By Disease Name
No filters selected
By Drug Name
No filters selected
By Themes
No filters selected
Showing 2 results out of 2
Data Insights
CWP-291 by JW Pharmaceutical for Relapsed Acute Myeloid Leukemia: Likelihood of Approval
CWP-291 is under clinical development by JW Pharmaceutical and currently in Phase II for Relapsed Acute Myeloid Leukemia. According to...
Data Insights
CWP-291 by JW Pharmaceutical for Refractory Acute Myeloid Leukemia: Likelihood of Approval
CWP-291 is under clinical development by JW Pharmaceutical and currently in Phase II for Refractory Acute Myeloid Leukemia. According to...